Financial Disclosures

In the interest of full transparency, Dr. Aguirre reports the following financial disclosures:
 
Consulting: Affini-T Therapeutics, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Celex Oncology, Curie.Bio, Incyte, Kestrel Therapeutics, Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Pfizer, Plexium, Quanta Therapeutics, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, Taiho Pharmaceuticals, T-knife Therapeutics, Third Rock Ventures, and Ventus Therapeutics. 

Equity: Riva Therapeutics and Kestrel Therapeutics

Research Funding: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Nimbus Therapeutics, Novartis, Novo Ventures, Revolution Medicines, Syros Pharmaceuticals, and Verastem.

Updated: April 14, 2025